Interestingly, recent studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i) may reduce the risk of hyperkalemia when coadministered with mineralocorticoid receptor antagonists. This evidence concerns the gene NR3C2 and Hyperkalemia.